Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12611000148976
Ethics application status
Approved
Date submitted
8/02/2011
Date registered
8/02/2011
Date last updated
2/07/2013
Type of registration
Prospectively registered
Titles & IDs
Public title
Does Metformin improve vascular function in youth with Type 1 diabetes
Query!
Scientific title
Does Metformin improve vascular function in youth with Type 1 Diabetes
Query!
Secondary ID [1]
253462
0
REC2327/12/13
Query!
Universal Trial Number (UTN)
U1111-1119-3513
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Type 1 diabetes
261015
0
Query!
Obesity
261016
0
Query!
Vascular health
261017
0
Query!
Condition category
Condition code
Metabolic and Endocrine
259153
259153
0
0
Query!
Diabetes
Query!
Cardiovascular
259154
259154
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Diet and Nutrition
259279
259279
0
0
Query!
Obesity
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Administration of Metformin tablets: If weight > 60kg - 500mg daily for 2 weeks increased to 1g twice daily over the following 6 weeks, then 1g twice daily for 12 months. For weight < 60kg - 500mg daily for 2 weeks then 500mg twice daily for 6 months. Dietary advice - session with a dietician (1 hour) at the commencement of the study and a review at 3 months (1 hour) a written information sheet will be provided. Activity data will be collected prior each dietary assessment using a SensWear device (external device worn over the upper arm - like a watch) for 5 days.
Query!
Intervention code [1]
257905
0
Prevention
Query!
Intervention code [2]
257999
0
Treatment: Drugs
Query!
Comparator / control treatment
placebo tablet containing: sodium starch glycolate (type A0, Povidone, maize starch, magnesium sterate, silica, colloidal anhydrous, hypromellose, macrogol 6000, purified talc, titanium dioxide. The tablets are identical to the metformin 500mg tablet aside from the absence of metformin. The placebo group also receive dietary advice
There will be an additional baseline comparator group of non Type 1 Diabetes participants. They will be recruited based on the same criteria as the T1D population (but will not have the diagnosis of T1D). This population will not receive the intervention and will have a single baseline assessment.
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
262079
0
Vascular function (flow mediated dilatation and Glyceryl trinitrate induced dilatation)
Query!
Assessment method [1]
262079
0
Query!
Timepoint [1]
262079
0
0, 3, 6, 12 months
Query!
Secondary outcome [1]
273113
0
serum adiponectin/leptin ratio
Query!
Assessment method [1]
273113
0
Query!
Timepoint [1]
273113
0
0, 3, 6, 12
Query!
Secondary outcome [2]
273114
0
Waist circumference
Query!
Assessment method [2]
273114
0
Query!
Timepoint [2]
273114
0
0, 3, 6, 12 months
Query!
Secondary outcome [3]
273115
0
Body mass index
Query!
Assessment method [3]
273115
0
Query!
Timepoint [3]
273115
0
0, 3, 6, 12 months
Query!
Secondary outcome [4]
273116
0
Body composition assessed by DEXA (nuclear medicine study)
Query!
Assessment method [4]
273116
0
Query!
Timepoint [4]
273116
0
0, 12 months
Query!
Secondary outcome [5]
273117
0
Insulin requirements - calculated from total daily dose of insulin
Query!
Assessment method [5]
273117
0
Query!
Timepoint [5]
273117
0
0, 3, 6, 12 months
Query!
Secondary outcome [6]
273118
0
whole blood HbA1c
Query!
Assessment method [6]
273118
0
Query!
Timepoint [6]
273118
0
0, 3, 6, 12 months
Query!
Secondary outcome [7]
273119
0
Fasting serum Lipids
Query!
Assessment method [7]
273119
0
Query!
Timepoint [7]
273119
0
0, 3, 6, 12 months
Query!
Secondary outcome [8]
273137
0
serum HsCRP
Query!
Assessment method [8]
273137
0
Query!
Timepoint [8]
273137
0
0, 3, 6, 12 months
Query!
Secondary outcome [9]
276521
0
Retinal photograph
Query!
Assessment method [9]
276521
0
Query!
Timepoint [9]
276521
0
0, 12 months
Query!
Eligibility
Key inclusion criteria
Body Mass Index > 50th centile for age Type 1 Diabetes duration greater than 1 year and insulin requirements > 0.5 units/kg/day
Baseline comparator group: Body Mass Index > 50th centile for age
Query!
Minimum age
8
Years
Query!
Query!
Maximum age
18
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
non type 1 diabetes Severe hypoglycaemic episode in the previous 6 months Recurrent Diabetic ketoacidosis (> 2 episode in the previous year) History of smoking OR serum cotinine level > 28 nmol/L Other serious comorbidities (eg liver and renal disease) Contraindications to metformin therapy (hypersensitivity, renal or liver dysfunction, Vitamin B12 deficiency) Inability to abstain from alcohol Pregnancy or breastfeeding Subjects already taking metformin, oral contraceptives, antihypertensives, multivitamins or statins
Baseline comparator group: type 1 diabetes or non type 1 diabetes History of smoking OR serum cotinine level > 28 nmol/L Other serious comorbidities (eg liver and renal disease) Pregnancy or breastfeeding Subjects already taking metformin, oral contraceptives, antihypertensives, multivitamins or statins
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Each participant will be assigned a unique identifier. Pharmacy staff will dispense the intervention (either metformin or placebo) in bottles which do not specify whether they contain metofrmin or placebo (the label reads "metformin or placebo" and could contain either).
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using computer sofware sequence generation
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
9/02/2011
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
76
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
722
0
Womens and Childrens Hospital - North Adelaide
Query!
Recruitment hospital [2]
1196
0
Flinders Medical Centre - Bedford Park
Query!
Funding & Sponsors
Funding source category [1]
258442
0
Commercial sector/Industry
Query!
Name [1]
258442
0
Paediatric Endocrine Research Grant (Pfizer Australia)
Query!
Address [1]
258442
0
38-42 Wharf Road West
Ryde NSW 2114
Query!
Country [1]
258442
0
Australia
Query!
Funding source category [2]
258456
0
Charities/Societies/Foundations
Query!
Name [2]
258456
0
WCH foundation
Query!
Address [2]
258456
0
WCH foundation
Research Secretariat
72 King William Street
North Adelaide SA
5006
Query!
Country [2]
258456
0
Australia
Query!
Primary sponsor type
Individual
Query!
Name
Alexia Pena
Query!
Address
Endocrine Department
72 King William Street
Women's and Children's Hosptial
North Adelaide SA
5006
Query!
Country
Australia
Query!
Secondary sponsor category [1]
257588
0
Individual
Query!
Name [1]
257588
0
Prof Jennifer Couper
Query!
Address [1]
257588
0
Endocrine Department
72 King William Street
Women's and Childrens Hospital
North Adelaide SA
5006
Query!
Country [1]
257588
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
260430
0
Children, Youth and Women's Health Service (CYWHS) Human Research Ethics Committee
Query!
Ethics committee address [1]
260430
0
Women's and Children's Hospital
Research Secretariat
72 King William Street
North Adelaide
SA 5006
Query!
Ethics committee country [1]
260430
0
Australia
Query!
Date submitted for ethics approval [1]
260430
0
Query!
Approval date [1]
260430
0
25/01/2011
Query!
Ethics approval number [1]
260430
0
2327/13/12
Query!
Summary
Brief summary
Cardiovascular disease is the leading cause of mortality in type 1 diabetes (T1D). Prevention of vascular complications of diabetes requires strategies that begin early in the disease process. Risk factors in childhood track into adulthood and correlate with early markers of atherosclerosis such as vascular endothelial and smooth muscle function.
We have shown that children and adolescents with type 1 diabetes have detectable endothelial and smooth muscle dysfunction that relate to body mass index (BMI). A significant number of youth with T1D are also overweight with insulin resistance. Metformin reduces insulin requirements and weight gain in type 1 diabetes. In type 2 diabetes Metformin substantially reduces risk of cardiovascular events and improves endothelial function. However there are no studies of cardiovascular outcomes or their earlier cardiovascular markers in type 1 diabetes despite the increasing prevalence of overweight status in this population and the fact that this is a major modifiable risk factor for cardiovascular disease.
Determining the effect of Metformin on vascular function in overweight youth with type 1 diabetes in a double blind randomized placebo controlled parallel trial will provide additional strategies to intervene in early in the process of atherosclerosis.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
32126
0
Dr Alexia Pena
Query!
Address
32126
0
72 King William St
North Adelaide SA
5006
Query!
Country
32126
0
Australia
Query!
Phone
32126
0
+61 8 8161 7000
Query!
Fax
32126
0
Query!
Email
32126
0
[email protected]
Query!
Contact person for public queries
Name
15373
0
Dr Dr Alexia Pena
Query!
Address
15373
0
Endocrine Department
Women's and Children's Hosptial
72 King William Street
North Adelaide SA
5006
Query!
Country
15373
0
Australia
Query!
Phone
15373
0
+61 8 8161 8134
Query!
Fax
15373
0
+61 8 8161 7759
Query!
Email
15373
0
[email protected]
Query!
Contact person for scientific queries
Name
6301
0
Dr Dr Alexia Pena
Query!
Address
6301
0
Endocrine Department
Women's and Children's Hosptial
72 King William Street
North Adelaide SA
5006
Query!
Country
6301
0
Australia
Query!
Phone
6301
0
+61 8 81618134
Query!
Fax
6301
0
+61 8 8161 7759
Query!
Email
6301
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Current supporting documents:
Updated to:
Doc. No.
Type
Citation
Link
Email
Other Details
Attachment
23188
Study protocol
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Embase
Early atherosclerosis is associated with retinal microvascular changes in adolescents with type 1 diabetes.
2018
https://dx.doi.org/10.1111/pedi.12764
Embase
Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?.
2018
https://dx.doi.org/10.1016/S2213-8587%2818%2930035-4
Embase
Effect of metformin on vascular function in children with type 1 diabetes: A 12-month randomized controlled trial.
2017
https://dx.doi.org/10.1210/jc.2017-00781
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF